Sector › Medicine

Press Releases

エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において優先審査品目に指定

Jan 30, 2023 09:00 JST

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency

Jan 27, 2023 10:46 HKT/SGT

エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理

Jan 27, 2023 08:30 JST

Cantor Fitzgerald首次覆盖普瑞健康予“增持”评级

Jan 26, 2023 12:21 HKT/SGT

Cantor Fitzgerald首次覆蓋普瑞健康予“增持”評級

Jan 26, 2023 12:19 HKT/SGT

Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

Jan 26, 2023 12:16 HKT/SGT

医思健康料23财年第三季销售额按年升不少于8%

Jan 20, 2023 19:33 HKT/SGT

醫思健康料23財年第三季銷售額按年升不少於8%

Jan 20, 2023 19:32 HKT/SGT

EC Healthcare Expects Third Quarter FY23 Sales Volume to Increase no less than 8% YoY

Jan 20, 2023 19:31 HKT/SGT

Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel

Jan 19, 2023 09:35 HKT/SGT

エーザイ、イスラエルの医薬品販売子会社が事業活動を開始

Jan 19, 2023 09:00 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company

Jan 19, 2023 08:07 HKT/SGT

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

Jan 18, 2023 12:28 HKT/SGT

エーザイ、米国臨床腫瘍学会消化器がんシンポジウム2023において消化器系がんに対する治療薬の最新の開発研究の演題を発表

Jan 18, 2023 08:30 JST

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Jan 16, 2023 17:56 HKT/SGT

Fujitsu and Sapporo Medical University launch joint project to realize data portability in the healthcare field

Jan 16, 2023 10:17 HKT/SGT

エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請

Jan 16, 2023 09:00 JST

Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024

Jan 16, 2023 06:00 HKT/SGT

エーザイ、サステナビリティページリニューアルのお知らせ

Jan 13, 2023 17:00 JST

Eisai Launches Renewed Sustainability Page

Jan 13, 2023 14:06 HKT/SGT